{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022488","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.641262+00:00","generated_at":"2026-06-22T05:14:10.843212+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ono exercises option to Fate's HER2 CAR T-cell candidate; Fate to receive $12.5M","bullets":["Ono exercised option to FT825/ONO-8250, triggering $12.5M option exercise fee to Fate.","Fate and Ono to jointly develop and commercialize the candidate in the U.S. and Europe; Ono has exclusive rights elsewhere.","Preclinical data showed broad, potent anti-tumor activity against HER2-low tumor cells.","Fate eligible for additional clinical, regulatory, and commercial milestones plus tiered royalties on sales outside US/EU.","Collaboration expanded to include a second solid tumor antigen program for preclinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022488","json":"https://secwatch.observer/filing/0000950170-22-022488.json","markdown":"https://secwatch.observer/filing/0000950170-22-022488.md","text":"https://secwatch.observer/filing/0000950170-22-022488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/0000950170-22-022488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/fate-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:14:10.843212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53211566fe199bf1338b60d4c545d8eaf39186ce","claim":"FATE THERAPEUTICS INC entered into Letter Agreement with Ono Pharmaceutical Co., Ltd. valued at $12.5 million (effective 2022-11-07).","evidence_excerpt":"On November 7, 2022, Fate Therapeutics, Inc. (“Fate”) and Ono Pharmaceutical Co., Ltd. (“Ono”) entered into a letter agreement (“Letter Agreement”) in connection with the Collaboration and Option Agreement between Fate and Ono dated September 14, 2018, as amended by a letter agreement dated December 4, 2020 and an amendment dated June 28, 2022 (the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/0000950170-22-022488-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Ono Pharmaceutical Co., Ltd."},{"label":"Value","value":"$12.5 million"},{"label":"Effective","value":"2022-11-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}